Reviews
Vol. 38 (2026)
https://doi.org/10.4081/uij.2026.370

Sexual function outcome in erbium-doped yttrium aluminum garnet laser versus topical estrogen among postmenopausal patients: a systematic review

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 14 September 2026
0
Views
0
Downloads
Erbium-doped yttrium aluminum garnet laser, genitourinary syndrome of menopause, sexual satisfaction, FSFI

Authors

Raymond Surya Tan
raymond.surya@trisakti.ac.id
Faculty of Medicine, Universitas Trisakti, Jakarta; Department of Obstetrics and Medicine, RSUD Tarakan, Jakarta; Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran/Kemenkes Hasan Sadikin Hospital, Bandung, Indonesia.
Ekarini Aryasatiani
Department of Obstetrics and Medicine, RSUD Tarakan, Jakarta; Faculty of Medicine and Health Sciences, Universitas Kristen Krida Wacana, Jakarta, Indonesia.
RM Sonny Sasotya
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran/Kemenkes Hasan Sadikin Hospital, Bandung, Indonesia.
Budi Iman Santoso
Department of Obstetrics and Medicine, Faculty of Medicine, Universitas Indonesia/Kemenkes Dr Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Genitourinary syndrome of menopause (GSM) is a symptom affecting both the urinary tract and vagina due to decreased sex hormones, especially estrogen, during menopause. This study aims to compare the efficacy of vaginal erbium-doped yttrium aluminum garnet (Er-YAG) laser therapy and topical estrogen treatment in managing GSM. A systematic literature search was conducted following PRISMA guidelines, utilizing electronic databases. The databases searched included PubMed, Scopus, Google Scholar, and the Cochrane Library. Clinical trials are included that evaluate GSM patients treated with vaginal Er-Yag laser therapy. All studies were assessed for risk of bias using the Newcastle-Ottawa scale. Among 695 studies in the initial search, only three cohorts are eligible in this review, representing the analysis of 546 patients across the globe. Our analysis shows vaginal dryness and dyspareunia significantly decreased (60% asymptomatic for dyspareunia, 30% for dryness at 12 months; VAS for dryness/dyspareunia decreased from 8.3/8.5 to 5.6/5.3 at 12 months). Vaginal health indicators also improved: the vaginal health index score increased (10.6 to 16.5), maturation value significantly increased (20.8 to 52.2; median 5 to 80), vaginal pH decreased, and sexual satisfaction (e.g., orgasm frequency p=0.007) in the laser group compared to the estrogen group. Compelling evidence shows the efficacy of Er-YAG laser therapy in improving sexual function outcomes and alleviating symptoms associated with GSM more than topical estrogen therapy.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause 2022;29:767-94.
Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause 2014;21:1063-8.
Nappi RE, Palacios S, Bruyniks N, et al. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause 2019;26:485-91.
Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016;215:704-11.
Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016;2016:CD001500.
Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women’s Sexual Health. Menopause 2018;25:596-608.
Jha S, Wyld L, Krishnaswamy PH. The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis. Clin Breast Cancer 2019;19:e556-62.
Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016;19:151-61.
Bruyniks N, Biglia N, Palacios S, Mueck AO. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 2017;20:195-204.
Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363-9.
Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturitas 2017;99:10-15.
Lapii GA, Yakovleva AY, Neimark AI. Structural reorganization of the vaginal mucosa in stress urinary incontinence under conditions of Er:YAG laser treatment. Bull Exp Biol Med 2017;162:510-4.
Filippini M, Porcari I, Ruffolo AF, et al. CO2-laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis. J Sex Med 2022;19:452-70.
Mension E, Alonso I, Tortajada M, et al. Vaginal laser therapy for genitourinary syndrome of menopause - systematic review. Maturitas 2022;156:37-59.
Pessoa LLMN, de Souza ATB, Sarmento ACA, et al. Laser therapy for genitourinary syndrome of menopause: systematic review and meta-analysis of randomized controlled trial. Rev Bras Ginecol Obstet 2024;46:e-rbgo38.
Gaspar A, Addamo G, Brandi H. Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. Am J Cosmet Surg 2011;28:156-62.
Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 2018;25:21-8.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.
Gambacciani M, Levancini M, Russo E, et al. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric 2018;21:148-52.
Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med 2017;49:160-8.
Qi Y, Sun C, Zhou Y, et al. Efficacy of transvaginal erbium laser treatment for vaginal relaxation and its impact on vaginal microenvironment indicators. Am J Transl Res 2025;17:2701-11.
Gambacciani M, Cervigni M, Gaspar A, et al. Safety of vaginal erbium laser: a review of 113,000 patients treated in the past 8 years. Climacteric 2020;23:S28-32.
Gambacciani M, Albertin E, Torelli MG, et al. Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study. Climacteric 2020;23:S24-7.

How to Cite



Sexual function outcome in erbium-doped yttrium aluminum garnet laser versus topical estrogen among postmenopausal patients: a systematic review. (2026). Urogynaecologia International Journal, 38. https://doi.org/10.4081/uij.2026.370
Copyright (c) 2026 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.